Futura Medical’s James Barder talks to Proactive’s Katie Pilbeam about its interim results for the six months ended 30 June 2022.
He says it’s been a constructive and productive six months.The operational highlights include getting MED3000 ready to be the first pan-European topical treatment for erectile dysfunction (“ED”) available without a doctor’s prescription.
And in the US, Futura received highly positive results from the confirmatory Phase 3 clinical study, (FM71) for MED3000 for the treatment of ED meeting all primary and secondary endpoints in August.
